IPM Take
Alzheimer’s blood biomarkers have spent years proving that they can detect disease biology. The PLASMAR trial asks the more important health-system question: does knowing the result earlier actually change care?
The answer appears to be yes. At three months, clinicians reached a very high-confidence etiological diagnosis in 50%of patients who received earlier biomarker disclosure compared with 4.6% in the delayed-disclosure arm. Earlier disclosure also accelerated therapeutic and follow-up decisions without worsening anxiety or depressive symptoms.
That shifts blood biomarkers from laboratory innovation toward care-pathway infrastructure.
Executive Summary
The Barcelona-based randomised trial included 220 participants with subjective cognitive decline, mild cognitive impairment or mild dementia. Participants were assigned to earlier or delayed disclosure of plasma p-tau217 and neurofilament light results.
At three months, very high-confidence etiological diagnoses were recorded in 56 of 112 participants in the early-disclosure group versus 5 of 108 in the delayed group. After both groups ultimately received results, diagnostic certainty converged, suggesting that the biomarker information itself was driving the difference.
Earlier disclosure also influenced treatment decisions and follow-up plans, while patient-reported anxiety, depression and quality of life did not worsen. The study was not designed to determine whether earlier biomarker-informed management improves cognition or disease course.
Why it matters
- Blood biomarkers are becoming easier to order than PET scans or lumbar punctures, which creates an opportunity to shorten diagnostic pathways. But their value depends on what clinicians do with the result.
- The trial also addresses one common concern: telling patients about Alzheimer-related biology earlier did not produce measurable psychological harm within this structured disclosure model. That finding supports implementation, but it should not be mistaken for permission to hand over results without counselling.
The Alzheimer’s biomarker debate has often focused on analytical performance: sensitivity, specificity, cut-offs and comparison with amyloid PET or cerebrospinal fluid. Those questions were necessary, but they were never sufficient.
A diagnostic test becomes clinically important when it changes decisions.
PLASMAR provides unusually strong evidence on that point because it randomised the timing of biomarker disclosure rather than merely asking clinicians retrospectively whether the information was useful. Early access to p-tau217 and NfL sharply increased diagnostic certainty and prompted earlier management changes.
That matters at a moment when Alzheimer’s disease-modifying therapy increasingly depends on biological confirmation. A slow diagnostic pathway can now mean more than uncertainty; it may determine whether a patient remains within a treatment window.
The study also shows why implementation needs nuance. Intermediate biomarker values generated less certainty than clear high- or low-likelihood results, and the trial took place in a specialised memory-clinic setting with structured disclosure. Those conditions will not automatically exist in primary care.
The next Alzheimer’s blood-test story is therefore not about whether the assays work. It is about whether health systems can build the interpretation, counselling and referral pathway around them without creating a new diagnostic bottleneck.
